News|Articles|October 1, 2012

Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis

Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.


Related to this article

Stafeeva-stock@adobe.com
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.